Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine TQT Study
NCT02737605Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine in treatment-resistant depression (TRD) and major depressive disorder (MDD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Mean Change From Baseline in QTc Interval and Percentage of Participants With Maximum Change From Baseline in Electrocardiogram (ECG) Morphology. Started Jul 2016; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02737605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737605.